Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Chinese Medical Journal ; (24): 269-273, 2010.
Article in English | WPRIM | ID: wpr-314600

ABSTRACT

<p><b>BACKGROUND</b>For patients with end-stage lung diseases, lung transplantation is the final therapeutic option. Sequential double-lung transplantation is recognized as an established procedure to avoid cardiopulmonary bypass (CPB). But some of the sequential double-lung transplantations require CPB support during the surgical procedure for various reasons. However, conventional CPB may increase the risk of bleeding and early allograft dysfunction. Extracorporeal membrane oxygenation (ECMO) is more advantageous than conventional CPB during the perioperative period of transplantation. Replacing traditional CPB with ECMO is promising for those patients needing cardiopulmonary support during a sequential double-lung transplantation procedure. This study aimed to summarize the preliminary experience of ECMO practice in lung transplantation.</p><p><b>METHODS</b>Between November 2002 and October 2008, twelve patients with end-stage lung diseases undergoing sequential double-lung transplantation were subjected to ECMO during the surgical procedure. Eleven patients were prepared for the procedure via transverse thoracostomy (clamshell) and cannulated through the ascending aorta and right atrium for ECMO. The first patient who underwent bilateral thoracotomy for bilateral sequential lung transplantation required emergency ECMO via the femoral artery and vein during the second lung implantation. The Medtronic centrifugal pump and ECMO package (CB1V97R1, Medtronic, Inc., USA) were used for all of the patients.</p><p><b>RESULTS</b>During ECMO, the blood flow rate was set between 1.8 - 2.0 L x m(-2) x min(-1) to keep hemodynamic and oxygen saturation stable; colloid oncotic pressure was maintained at more than 18 mmHg with albumin and hematocrit (HCT) kept at 28% or more. Two patients died early in this series and the other 10 patients were weaned from ECMO successfully. The duration of ECMO was 1.38 - 67.00 hours, and postoperative intubation was 10.5 - 67.0 hours.</p><p><b>CONCLUSIONS</b>As an established technique of cardiopulmonary support, ECMO is helpful to keep hemodynamics stable, while reducing risk factors such as ischemia-reperfusion injury, anticoagulation requirement and systemic inflammatory response for sequential double-lung transplantation compared with conventional CPB.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Cardiopulmonary Bypass , Extracorporeal Membrane Oxygenation , Methods , Lung Diseases , General Surgery , Lung Transplantation , Methods , Treatment Outcome
2.
Chinese Journal of Surgery ; (12): 818-821, 2007.
Article in Chinese | WPRIM | ID: wpr-340910

ABSTRACT

<p><b>OBJECTIVE</b>To summarize the diagnosis and treatment of acute rejection after lung transplantation and to discuss optimized immunosuppressive therapy.</p><p><b>METHODS</b>Between November 2002 and June 2006, 16 patients underwent operations on lung transplantation, 7 cases on single-lung transplantation and 9 cases on bilateral-lung transplantation. Immunosuppressive therapy was new triple drug maintenance regimen including tacrolimus (Tac), mycophenolate mofetil (MMF) and steroids, and (or) daclizumab.</p><p><b>RESULTS</b>Eight cases in new triple drug maintenance regimen with daclizumab. There is no acute rejection in 6 months. Except 2 of the 8 cases died of early post-lung transplantation sever pulmonary edema and dysfunction, 3 of the rest 6 cases underwent acute rejection incident about 21.4% (3/14).</p><p><b>CONCLUSION</b>In this group the new triple drug maintenance regimen including tacrolimus (Tac), mycophenolate mofetil (MMF) and steroids, and (or) daclizumab acquired beneficial effect in preventing acute rejection after lung transplantation.</p>


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Antibodies, Monoclonal , Therapeutic Uses , Antibodies, Monoclonal, Humanized , Graft Rejection , Immunoglobulin G , Therapeutic Uses , Immunosuppressive Agents , Therapeutic Uses , Lung Transplantation , Mycophenolic Acid , Therapeutic Uses , Postoperative Complications , Prednisone , Therapeutic Uses , Tacrolimus , Therapeutic Uses , Treatment Outcome
3.
Chinese Journal of Surgery ; (12): 72-74, 2004.
Article in Chinese | WPRIM | ID: wpr-311148

ABSTRACT

<p><b>OBJECTIVE</b>To explore the "hemi-clamshell" approach to the resection of the apical chest tumors, and to evaluate its advantages of operative safety and completeness.</p><p><b>METHODS</b>We conducted a retrospective review of the records of 27 patients undergoing resection of the primary apical chest tumors from January 1995 to January 2001. Tumor type included NSCLC, sarcoma, neurofibromatosis, esophageal carcinoma. Data collected included clinical presentation, tumor type and involvement, type of resection, complication, and survival.</p><p><b>RESULTS</b>A clinical operation for gross-total resection of tumors and invaded structures was performed on six patients by means of a successful anterior approach. Among other 21 patients on whom a clinical operation was performed by posterior approach, only 13 patients obtained gross-total resection. There were significant difference between the two groups (P < 0.01). The mean duration for follow-up was 29 months, and the overall median survival was 21 months. Median survival in patients undergoing gross-total resection was 29 months, and this is significantly better than in incomplete resection group (P < 0.01).</p><p><b>CONCLUSIONS</b>The anterior "hemi-clamshell" approach is a successful technique for the exposure and resection of these tumors and invaded structures. Release of symptoms and long-term survival is acceptable if complete resection can be performed.</p>


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Follow-Up Studies , Lung Neoplasms , General Surgery , Neoplasms , General Surgery , Prognosis , Retrospective Studies , Thoracic Surgical Procedures , Methods , Thorax , Pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL